Skip to Content

ApoGen Receives $7 Million Investment for Cancer Therapy

Researcher with pipettes and petri dishes

A University of Minnesota startup recently attracted a major investment to support continued development of drug therapies that make cancer treatments more effective.

ApoGen Biotechnologies Inc., launched in October 2014, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells and to move these treatments toward clinical trials. ApoGen is based on discoveries by two U researchers: Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics; and Daniel Harki, Ph.D., assistant professor of medicinal chemistry. John Santini Jr., Ph.D., is the company’s president and CEO.

Cancer therapies often become less effective over time as cancer cells become resistant to treatment. ApoGen’s drugs are designed to block a key enzyme that causes drug resistance, potentially making current and future treatments more effective.

“I have been working with Drs. Harris and Harki to move ApoGen’s science toward clinical and commercial development, and I am thrilled to now partner with Accelerator Corporation,” Santini said in a press release. “We believe that we have assembled the ideal team to advance our therapeutic technologies to slow or stop tumor evolution, which has the potential to yield a significant clinical impact for cancer patients.”

Russ Straate, associate director of the Venture Center, part of the U’s Office for Technology Commercialization, said Accelerator Corporation’s investment marks a milestone for ApoGen.

“For a startup that aims to develop a therapy based on innovative research and bring it to market, an investment like this is crucial,” Straate said. “This funding will help ApoGen in its next steps toward clinical trials and move it closer to the ultimate goal of getting this unique cancer therapy into the hands of those who can benefit from it.”

For more on the Accelerator Corporation’s investment in ApoGen, see the College of Biological Sciences blog.

Kevin Coss

Kevin Coss

Kevin is a writer with the Office of the Vice President for Research.

coss@umn.edu

Latest Blog Posts

Sun setting over a prarie scene

After eight productive years, we are phasing out the Inquiry blog and launching a new monthly newsletter focused on news, information, and resources for our systemwide research community.

Read More
Dr. Friedemann-Sanchez and Dr. Grieve sitting at a table together.

In 2018, two University of Minnesota researchers traveled to a United Nations council meeting to advocate for changes to address an epidemic of violence against women in Colombia.

Read More
Senior man speaks with a health care provider while looking at a digital display

Researchers aim to help train pharmacists and educate patients with the goal of improving medication outcomes for groups with higher rates of kidney failure.

Read More
Sironix banner in a laboratory space

Sironix Renewables uses a patented method to make nontoxic, sustainably-sourced surfactants that replace their counterparts made from petroleum.

Read More

Announcements for the UMN Research Community